Nachrichten zur Agios Pharmaceuticals Aktie

Agios reports final data analysis in late-stage trial for rare cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

– Supplemental New Drug Application Planned for Submission in Q1 2021 – – Supplemental New Drug Application Planned for Submission…

Agios Pharmaceuticals (AGIO) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios highlights 2021 milestones, sees filing for sickle cell drug U.S. approval in Q2

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency…

Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…

Agios Pharmaceuticals: A Pivot From Cancer Metabolism To Rare Diseases

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?

Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately....…

Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up

Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

Agios Stock Is Soaring Because of a Major Sale

Agios stock is soaring in Monday trading after announcing the sale of its cancer products. The company will focus on…

Why Agios Pharmaceuticals Stock Is Soaring Today

Investors applauded the companys planned sale of its oncology portfolio....…

Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?

NEW YORK , Dec. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGIO,…

Agios Soars on Plan to Sell Cancer Drugs, Return $1.2B to Holders

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios shares jump 20% after announcing plans to sell cancer portfolio

Shares of Agios Pharmaceuticals Inc. soared 20.6% in premarket trading on Monday after the company said it is selling…

Agios to Sell Its Cancer Portfolio to Servier for $1.8 Billion

Agios to Sell Its Cancer Portfolio to Servier for $1.8 Billion...…

Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties

– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building…

Agios Pharmaceuticals (AGIO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Unusual Options Activity Insight: Agios Pharmaceuticals

On Friday, shares of Agios Pharmaceuticals (NASDAQ: AGIO) saw unusual options activity. After the option alert, the stock price moved…

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field…

Agios Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals Inc (AGIO) Q3 2020 Earnings Call Transcript

AGIO earnings call for the period ending October 31, 2020....…

AGIOS PHARMACEUTICALS, INC.: 10-Q Report

10-Q...…

Agios Pharmaceuticals EPS misses by $0.06, misses on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals Q3 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting

Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET Company to Host…

Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…

Agios: A Look At Mitapivat In Anaemia, Its Backup Indication

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios (AGIO) Withdraws Filing for Leukemia Drug Tibsovo in EU

Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in…

Agios: A Look At TIBSOVO In CC Patients

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios falls after pulling European marketing application for Tibsovo

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO® in Newly Diagnosed AML Patients –...…

All You Need to Know About Agios Pharmaceuticals (AGIO) Rating Upgrade to Buy

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…

Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

– Supplemental New Drug Application Planned for Submission in Q1 2021 –...…